 CAMBRIDGE, Mass., June 01, 2022 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 2:30 p.m. EDT. 